All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from the Hospital Universitari Vall d’Hebron and colleagues have reported on the development of Hybri, a hybrid recombinant bispecific fusion protein with immunosuppressive activity that consists of the extracellular domain (ECD) of human PD-L2 fused via a linker to the ECD of human CTLA-4, further fused to the Fc domain of human IgG.
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection.
Gracell Biotechnologies Inc. is initiating two clinical trials in China in refractory systemic lupus erythematosus for lead candidate GC-012F, a CD19/B-cell maturation antigen dual-targeting CAR T.
The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a target in autoimmune disease that has evaded the best efforts of many other drug developers.
With age, senescent cells become detrimental to tissues. Mayo Clinic scientists have observed this phenomenon in the lung alveoli, where senescent macrophages accumulated in aging tissue and in early stages of non-small-cell lung cancer (NSCLC) driven by the Kras oncogene. “We found that the macrophages were present in the earliest stages of the disease. Strategies targeting these cells for elimination or preventing their accumulation would be worthwhile to test in other conditions (assuming we find they occur),” Darren Baker, a Mayo Clinic senescent cell biologist and senior author of the study, told BioWorld.
With the rise of antibiotic resistance, treatment options against Yersinia pestis bacteria that cause pneumonic plague could also become limited. Antibody treatment has been effective in animal models of plague, but no approved human vaccine exists against this fatal disease.
Urinary tract infections (UTIs) are often recurrent. The organism does not always establish an effective line of defense that protects from reinfection. The key lies in two reservoirs of bacteria and how tissue-resident memory T cells (TRMs) trigger the immune response. A recent paper from the Pasteur Institute in France describes how these cells mediate immunity to defeat reinfection.
Hilleman Laboratories Singapore Pte Ltd. and the Agency for Science, Technology and Research (A*STAR) have established a collaboration to explore using novel circular ribonucleic acid (circRNA) technology to develop a Nipah virus vaccine and to validate the technology platform for application for other infectious diseases pathogens.
The targeted delivery of optimized stem cells directly into injured tissues has been used to maximize efficacy and minimize systemic exposure. Still, despite hundreds of clinical trials evaluating mesenchymal stem cell (MSC) therapy as a treatment, clinical efficacy remains highly variable. Investigators at Case Western Reserve University have developed an optimized combination of cytokines and growth factors applied to MSCs (HXB-319).
RSS
